BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34508650)

  • 1. Ischemic stroke as a presenting manifestation of polycythemia vera: a narrative review.
    Burattini M; Falsetti L; Potente E; Rinaldi C; Bartolini M; Buratti L; Silvestrini M; Viticchi G
    Rev Neurosci; 2022 Apr; 33(3):303-311. PubMed ID: 34508650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ischemic stroke as an initial performance of polycythemia vera in young adults: A case report and literature review.
    Hui S; Zhao J; Huo T; Dong L; Xie Y; Wang X; Zhang M
    Medicine (Baltimore); 2024 Feb; 103(7):e36953. PubMed ID: 38363912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Gadisseur A; Lam KH; De Raeve H; Schroyens W
    Acta Haematol; 2015; 133(1):56-63. PubMed ID: 25116182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
    Lengfelder E
    Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.
    Crodel CC; Jentsch-Ullrich K; Reiser M; Jacobasch L; Sauer A; Tesch H; Ulshöfer T; Wunschel R; Palandri F; Heidel FH
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2693-2705. PubMed ID: 34807311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microrheological disorders in patients with polycythemia vera suffered acute ischemic stroke.
    Tanashyan M; Shabalina A; Roitman E
    Mol Cell Biochem; 2022 Apr; 477(4):989-994. PubMed ID: 34984595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I treat polycythemia vera.
    Passamonti F
    Blood; 2012 Jul; 120(2):275-84. PubMed ID: 22611155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
    Maffioli M; Mora B; Passamonti F
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycythemia vera and the Jak2(V617F) mutation in a case of hereditary spherocytosis.
    Fleischman RA
    Am J Med Sci; 2013 Oct; 346(4):328-30. PubMed ID: 23588264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thrombosis in myeloproliferative neoplasms].
    Asakura H
    Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and therapy of polycythemia vera.
    Lengfelder E; Merx K; Hehlmann R
    Semin Thromb Hemost; 2006 Apr; 32(3):267-75. PubMed ID: 16673281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.